ArticleBMC ophthalmology2021
Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study.
Article in BMC ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A comparative study on the efficacy and safety of biosimilar (Rimmyrah) and reference ranibizumab in patients with diabetic macular edema.Frontiers in pharmacology · 2026Article
- Evaluation of the degree of agreement in the diagnosis of diabetic retinopathy between ophthalmologists and EyeArtInternational journal of retina and vitreous · 2025Article
- Cobalt Protoporphyrin Downregulates Hyperglycemia-Induced Inflammation and Enhances Mitochondrial Respiration in Retinal Pigment Epithelial Cells.Antioxidants (Basel, Switzerland) · 2025Article
- Ocular pharmacokinetics of intravitreal conbercept in a rabbit model following retinal scatter laser photocoagulation.Frontiers in pharmacology · 2025Article
- Efficacy comparison of multipoint and single point scanning panretinal laser photocoagulation in non-proliferative diabetic retinopathy treatment.World journal of diabetes · 2024Article
- Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial.Neural regeneration research · 2024Article
- Panretinal photocoagulation plus intravitreal conbercept for diabetic retinopathy in real world: a retrospective study.BMC ophthalmology · 2023Article
- Conbercept combined with laser photocoagulation in the treatment of diabetic macular edema and its influence on intraocular cytokines.World journal of diabetes · 2023Article
- A hypothetical therapeutic effect of light peripheral panretinal photocoagulation in neovascular age-related macular degeneration.Medical hypothesis, discovery & innovation ophthalmology journal · 2022Article
- Efficacy and Safety of Intravitreal Injection of Triamcinolone Acetonide and Conbercept for Intraocular Lens after Cataract Surgery.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Correction to: Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study.BMC ophthalmology · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPanretinal photocoagulation treatment (PRP) have been known as a standard treatment for proliferative diabetic retinopathy (PDR) or severe nonproliferative diabetic retinopathy (sNPDR). However, there is no consensus on when PRP should be administrated if anti-VEGF treatment is needed for the concurrent diabetic macular edema (DME). This study is to evaluate the difference between two groups of PRP prior to, or after intravitreal conbercept (IVC) for patients with PDR or sNPDR combined with DME.
methodsThis was a retrospective study. Fifty-eight eyes with DME secondary to PDR or sNPDR were divided into two groups; the PRP after (PRP-after group), or prior to (PRP-prior group), IVC. Changes in number of IVC injections, best corrected visual acuity (BCVA), and central subfield macular thickness (CSMT) were compared after 4 weeks, 12 weeks, 1 year, and 2 years from the first IVC injection.
resultsThe mean number of injections in PRP-after group was 4.8 (1 year) and 6.4 (2 year), lower than 6.4 (1 year) and 8.5 (2 year) in PRP-prior group (both p = 0.002). There was no significant difference in change in BCVA and CSMT between two groups after each follow-up.
conclusionPRP after IVC requires less injections but also yields similar visual and anatomic outcome comparing with PRP prior to IVC in patients with diabetic retinopathy combined with DME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.